The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 6, 2026 | Tregoning Kathleen | See Remarks | Grant(A) | 175K | — | $0 |
| Jun 9, 2026 | Renaud Ronald C JR | CEO & President, Director | Option exercise(M) | 38K | $5.25 | $200K |
| Jun 9, 2026 | Renaud Ronald C JR | CEO & President, Director | Option exercise(M) | 38K | — | $0 |
| Apr 20, 2026 | Bain Capital Investors LLC | 10% Owner | Conversion(C) | 17.9M | — | — |
| Apr 20, 2026 | Bain Capital Investors LLC | 10% Owner | Buy(P) | 8.4M | $16.00 | $134.4M |
| Apr 20, 2026 | Bain Capital Investors LLC | 10% Owner | Conversion(C) | 17.9M | — | $0 |
| Apr 20, 2026 | Kaplan Andrew T. | Director, 10% Owner | Conversion(C) | 17.9M | — | — |
| Apr 20, 2026 | Kaplan Andrew T. | Director, 10% Owner | Buy(P) | 8.4M | $16.00 | $134.4M |
| Apr 20, 2026 | Kaplan Andrew T. | Director, 10% Owner | Conversion(C) | 17.9M | — | $0 |
| Apr 20, 2026 | Koppel Adam | Director, 10% Owner | Conversion(C) | 16.9M | — | — |
| Apr 20, 2026 | Koppel Adam | Director, 10% Owner | Conversion(C) | 4.1M | — | — |
| Apr 20, 2026 | Koppel Adam | Director, 10% Owner | Buy(P) | 1.6M | $16.00 | $25.0M |
| Apr 20, 2026 | Koppel Adam | Director, 10% Owner | Conversion(C) | 16.9M | — | $0 |
| Apr 20, 2026 | Koppel Adam | Director, 10% Owner | Conversion(C) | 4.1M | — | $0 |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC | 10% Owner | Conversion(C) | 16.9M | — | — |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC | 10% Owner | Conversion(C) | 4.1M | — | — |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC | 10% Owner | Buy(P) | 1.6M | $16.00 | $25.0M |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC | 10% Owner | Conversion(C) | 16.9M | — | $0 |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC | 10% Owner | Conversion(C) | 4.1M | — | $0 |
| Apr 20, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% Owner | Conversion(C) | 9.5M | — | — |
| Apr 20, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% Owner | Conversion(C) | 2.0M | — | — |
| Apr 20, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% Owner | Conversion(C) | 5.0M | — | $0 |
| Apr 20, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% Owner | Conversion(C) | 709K | — | $0 |
| Apr 20, 2026 | RTW Investments, LP | 10% Owner | Conversion(C) | 10.3M | — | — |
| Apr 20, 2026 | RTW Investments, LP | 10% Owner | Buy(P) | 500K | $16.00 | $8.0M |
| Apr 20, 2026 | RTW Investments, LP | 10% Owner | Conversion(C) | 8.3M | — | — |
| Apr 20, 2026 | RTW Investments, LP | 10% Owner | Conversion(C) | 2.0M | — | — |
| Apr 16, 2026 | Coleman Jamie Beth | Chief Commercial Officer | Grant(A) | 75K | — | $0 |
| Apr 16, 2026 | Coleman Jamie Beth | Chief Commercial Officer | Grant(A) | 75K | — | $0 |
| Apr 16, 2026 | Akamine Scott | Chief Legal Officer | Grant(A) | 60K | — | $0 |
| Apr 16, 2026 | Akamine Scott | Chief Legal Officer | Grant(A) | 60K | — | $0 |
| Apr 16, 2026 | Cloghessy Paula | Chief People Officer | Grant(A) | 60K | — | $0 |
| Apr 16, 2026 | Cloghessy Paula | Chief People Officer | Grant(A) | 60K | — | $0 |
| Apr 16, 2026 | Burgess Paul D. | See Remarks | Grant(A) | 100K | — | $0 |
| Apr 16, 2026 | Burgess Paul D. | See Remarks | Grant(A) | 100K | — | $0 |
| Apr 16, 2026 | Kaplan Andrew T. | Director, 10% Owner | Grant(A) | 38K | — | $0 |
| Apr 16, 2026 | Koppel Adam | Director, 10% Owner | Grant(A) | 38K | — | $0 |
| Apr 16, 2026 | Clyburn Frank | Director | Grant(A) | 38K | — | $0 |
| Apr 16, 2026 | Pagan Douglas W. | Chief Financial Officer | Grant(A) | 100K | — | $0 |
| Apr 16, 2026 | Pagan Douglas W. | Chief Financial Officer | Grant(A) | 100K | — | $0 |
| Apr 16, 2026 | Wasserman Scott M. | Chief Medical Officer | Grant(A) | 100K | — | $0 |
| Apr 16, 2026 | Hite Christopher | Director | Grant(A) | 38K | — | $0 |
| Apr 16, 2026 | Wasserman Scott M. | Chief Medical Officer | Grant(A) | 100K | — | $0 |
| Apr 16, 2026 | Mackay Martin | Director | Grant(A) | 38K | — | $0 |
| Apr 16, 2026 | Milligan John F | Director | Grant(A) | 38K | — | $0 |
| Apr 16, 2026 | Renaud Ronald C JR | CEO & President, Director | Grant(A) | 300K | — | $0 |
| Apr 16, 2026 | Renaud Ronald C JR | CEO & President, Director | Grant(A) | 300K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-11. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).